In recent years there have been calls for increased scrutiny and enforcement of acquisitions by incumbent pharmaceutical firms of potentially competitive pipeline products. A popular narrative has emerged that such transactions are routinely entered into by large pharmaceutical companies to eliminate competitive threats by “killing” them. This article tells the other side of the story: these transactions frequently have strong procompetitive underpinnings, combining R&D expertise and put
...THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 18.223.160.61
Please verify email or join us to access premium content!